Galmed Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Allen Baharaff
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 32.36% |
| CEO tenure | 26yrs |
| CEO ownership | 0.7% |
| Management average tenure | 8.8yrs |
| Board average tenure | 10.1yrs |
Recent management updates
Recent updates
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
May 16
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 06Galmed GAAP EPS of -$0.15 beats by $0.09
Aug 04Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky
May 03Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 15Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
Oct 02Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?
May 20What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?
Feb 04
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth
Dec 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$9m |
| Jun 30 2025 | n/a | n/a | -US$9m |
| Mar 31 2025 | n/a | n/a | -US$7m |
| Dec 31 2024 | US$2m | US$553k | -US$8m |
| Sep 30 2024 | n/a | n/a | -US$6m |
| Jun 30 2024 | n/a | n/a | -US$6m |
| Mar 31 2024 | n/a | n/a | -US$6m |
| Dec 31 2023 | US$1m | US$551k | -US$7m |
| Sep 30 2023 | n/a | n/a | -US$8m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$1m | US$605k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$23m |
| Jun 30 2022 | n/a | n/a | -US$25m |
| Mar 31 2022 | n/a | n/a | -US$30m |
| Dec 31 2021 | US$3m | US$632k | -US$32m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$1m | US$503k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$27m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | -US$23m |
| Dec 31 2019 | US$1m | US$486k | -US$20m |
Compensation vs Market: Allen's total compensation ($USD1.71M) is above average for companies of similar size in the US market ($USD578.00K).
Compensation vs Earnings: Allen's compensation has increased whilst the company is unprofitable.
CEO
Allen Baharaff (60 yo)
Mr. Allen Baharaff has been the Chief Executive Officer of Galmed Pharmaceuticals Ltd. since January 2012 and has been its President since March 2015. Mr. Baharaff co-founded the Galmed Pharmaceuticals Ltd...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 26yrs | US$1.71m | 0.67% $ 31.1k | |
| Chief Financial Officer | 3.9yrs | US$295.25k | 0.11% $ 5.3k | |
| COO & Data Protection Officer | 8.8yrs | US$350.23k | 0.11% $ 5.3k | |
| Chief Accounting Officer | 3.9yrs | US$353.99k | 0.11% $ 5.3k | |
| Chief Scientific Officer | 9.3yrs | no data | 0% $ 0 | |
| Medical Consultant | 8.8yrs | US$382.51k | no data |
Experienced Management: GLMD's management team is seasoned and experienced (8.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | no data | US$1.71m | 0.67% $ 31.1k | |
| Lead Independent Director | 11.6yrs | no data | 0.057% $ 2.6k | |
| Independent Director | 8.6yrs | no data | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 19yrs | no data | 0.058% $ 2.7k | |
| Independent Director | 5.6yrs | no data | 0.057% $ 2.6k | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: GLMD's board of directors are seasoned and experienced ( 10.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 12:48 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galmed Pharmaceuticals Ltd. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Edward Nash | Canaccord Genuity |
| François Brisebois | Craig-Hallum Capital Group LLC |